Therapeutic advances in leiomyosarcomaKristine Peregrino Lacuna, Gary K. Schwartz, Sminu Bose et al.|Frontiers in Oncology|2023Cited by 49
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.Sminu Bose, Matthew Ingham, Shing M. Lee et al.|Journal of Clinical Oncology|2023Cited by 2
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.Kristine Peregrino Lacuna, Matthew Ingham, Shing M. Lee et al.|Journal of Clinical Oncology|2023Cited by 1